A team of researchers at The University of Texas MD Anderson Cancer Center has developed a nanotechnology platform that can change the way the immune system sees solid tumor cells, making them more receptive to immunotherapy. The preclinical findings suggest that this adaptable immune conversion approach has the potential for broad application across many cancer types.
An official website of the United States government.